NanoGroup S.A. signed an investment agreement for PLN 10.55 million with its main shareholder, Michal Lach, who simultaneously paid PLN 10.1 million. The funds to cover the aforementioned agreement came from the main shareholder’s sale of an equal number of shares on the regulated market, including through the ABB process, which was completed on December 11. As a result, NanoGroup has attracted new investors, including Polish TFIs.

Investment agreement

In accordance with the investment agreement, Michal Lach subscribed for 4.22 million shares in the Company at a price of PLN 2.50 as part of the ongoing issue of series N shares with a total value of PLN 10.55 million. Earlier, the Shareholder sold an equivalent number of shares on the regulated market. Some of them were sold during the accelerated book building (ABB) process.

ABB deal

As part of the ABB transaction, 2.4 million shares with a total value of PLN 6 million were sold. The transaction took place on December 9-11 this year. The process was coordinated by INC Brokerage. The remaining amount was raised through the sale directly by the major shareholder in transactions carried out on the regulated market.

New investors

As part of the transaction, Michal Lach sold the 4.22 million shares he held to Polish investors who became interested in the Company following its announcement of a strategic investment in Auxilius Pharma and the publication of its Development Strategy for 2026-2028.

Funding Objective

The funds raised by the issue will be used, among other things, to finalize the investment in Auxilius Pharma, a Polish pharmaceutical company specializing in the development of Value Added Medications (VAMs) – that is, formulations that use already researched and approved active substances, but in modern formulations that improve treatment efficacy and patient comfort, as announced on November 17. The investment in Auxilius Pharma is the second investment made as part of NanoGroup’s new growth strategy for 2026-2028.